PXD061196 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Aberrant SUMOylation restricts the targetable cancer immunopeptidome |
| Description | A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandomics and identified a function of activated SUMOylation in restricting the immunopeptidome landscape. Importantly, aberrant SUMOylation suppressed a unique HLA-I peptide and oncoprotein-derived neoepitope repertoire, enabling cancer cells to evade T cell immune surveillance. Mechanistically, SUMOylation impaired the immunoproteasome constitution and proteolytic activity, thus limiting the diversity of the peptide landscape. Further, SUMOylation altered TAP1 transporter binding preferences, thereby mimicking viral immune evasion strategies. As an actionable application, pharmacological inhibition of SUMOylation unmasked the targetable immunopeptidome and enhanced the tumor cell susceptibility to T cell killing. These findings highlight SUMOylation as a critical regulator of the adaptive anti-tumor immune response. We propose SUMO inhibition as a strategic approach to enhance immunogenic peptide presentation, thereby improving the efficacy of cancer immunotherapies. |
| HostingRepository | PRIDE |
| AnnounceDate | 2026-01-25 |
| AnnouncementXML | Submission_2026-01-25_14:57:12.197.xml |
| DigitalObjectIdentifier | https://dx.doi.org/10.6019/PXD061196 |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Supported dataset by repository |
| PrimarySubmitter | Martin Klatt |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606; |
| ModificationList | cysteinylation (disulfide with free L-cysteine); phosphorylated residue; monohydroxylated residue |
| Instrument | Q Exactive |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
|---|
| 0 | 2025-02-25 16:06:06 | ID requested | |
| ⏵ 1 | 2026-01-25 14:57:12 | announced | |
Publication List
Keyword List
| submitter keyword: SUMOylation,Immunpeptidome |
Contact List
| Martin Klatt |
|---|
| contact affiliation | Charité-University Medicine Berlin |
| contact email | martin.klatt@charite.de |
| lab head | |
| Martin Klatt |
|---|
| contact affiliation | Charite - University Medicine Berlin |
| contact email | martin.g.klatt@gmail.com |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/01/PXD061196 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD061196
- Label: PRIDE project
- Name: Aberrant SUMOylation restricts the targetable cancer immunopeptidome
